Browse studies

Find your next paid study

3,080 recruiting studies matching your filters

A Phase 2 Study of Preoperative Pembrolizumab and Chemotherapy Followed by Adjuvant Pembrolizumab in Resectable Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma

This research study is evaluating effectiveness and safety of a combination of immunotherapy drug, pembrolizumab, with chemotherapy, as a possible treatment be…

Head and Neck Squamous Cell CarcinomaHead and Neck CancerResectable Head and Neck Squamous Cell Carcinoma+2 more

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Dana-Farber Cancer InstituteNCT05726370

Phase 2

Single-Center Evaluation of the Clinical and Radiological Benefit of AHCC® in Combination with Standard of Care Treatment for HPV-Positive Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)

This is a phase 2, single-arm, open-label clinical trial determining safety and tolerability of AHCC in subjects with HPV-positive patients with Head and Neck …

HNSCCHead and Neck Squamous Cell Carcinoma

Estimated

~$75 – $2,000

Actual pay is set by the research site.

University of California, IrvineNCT06693323

Observational

Child Bipolar Network Ketogenic Diet Approach to Bipolar Disorder in Adolescents

The present study is an open trial of ketogenic diets for adolescents and young adults (ages 12-21 yrs) in the depressive or mixed phases of bipolar disorder (…

Bipolar Disorder (BD)Bipolar Disorder NOSBipolar Disorder I or II+2 more

Estimated

~$10 – $750

Actual pay is set by the research site.

University of California, Los AngelesNCT06920940

Phase 1

A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, …

ER+ HER2- Advanced Breast CancerHigh-grade Serous Ovarian Cancer (HGSOC)

Estimated

~$150 – $4,500

Actual pay is set by the research site.

AstraZenecaNCT06188520

Observational

Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) mHealth Randomized Controlled Hybrid Type I Effectiveness Implementation Trial

Men who are living with HIV and use stimulants face many challenges and barriers that may interfere with remembering to take their HIV medication. Forgetting t…

Behavioral InterventionViral Suppression of HIV InfectionART Adherence

Estimated

~$10 – $675

Actual pay is set by the research site.

University of California, San FranciscoNCT07125235

Phase 1

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors

This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor mic…

Head and Neck Squamous Cell CarcinomaSoft Tissue Sarcoma AdultTriple Negative Breast Cancer

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Pure Biologics S.A.NCT06700070

Phase 1

PHASE 1/2A OPEN-LABEL CLINICAL TRIAL EVALUATING VBC101, AN EGFR AND CMET TARGETED BI-SPECIFIC ANTIBODY DRUG CONJUGATE, IN PARTICIPANTS WITH ADVANCED SOLID TUMOR MALIGNANCIES

This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts an accelerated titration for the first dose level, followed …

Participants With Advanced Solid Tumor Malignancies

Estimated

~$150 – $4,200

Actual pay is set by the research site.

VelaVigo Bio IncNCT07136779

Ecological Momentary Assessment of State-Dependent Decision-Making and Metacognition Across a Psychopathology Continuum

Background: Making decisions during daily life is a complicated behavior. Even simple choices can be affected by a range of emotions, stresses, and moods. Men…

DepressionAnxietyAddiction+3 more

Estimated

~$10 – $675

Actual pay is set by the research site.

National Institute of Mental Health (NIMH)NCT07801079

Observational

Study to Evaluate the Clinical Utility of Radiation Exposure Reduction (SECURE): Multi-site Rampart Guardian Peripheral Trial

Radiation Protection

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Baylor Research InstituteNCT07467720

Phase 1

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS03 as a Single Agent in Participants With Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration

This is a first-in-human Phase I, multi-center, open-label study of ANS03 in patients with advanced solid tumors. The study evaluates the safety, tolerability,…

Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Avistone Biotechnology Co., Ltd.NCT06716138

Near-Infrared Diffuse Correlation Spectroscopy to Better Define the Pathophysiology of Peripheral Artery Disease

The goal of this study is to better understand how blood flows and how oxygen is utilized in the lower limbs of people who suffer from peripheral artery diseas…

Peripheral Artery Disease (PAD)

Estimated

~$10 – $750

Actual pay is set by the research site.

The University of Texas at ArlingtonNCT07313410

Phase 4

Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA for Treatment of Idiopathic and Neurogenic Overactive Bladder: a Randomized Trial

OnabotulinumtoxinA is an effective treatment for both idiopathic and neurogenic overactive bladder and was FDA approved for this indication in 2013. The standa…

Overactive Bladder

Estimated

~$25 – $1,000

Actual pay is set by the research site.

Walter Reed National Military Medical CenterNCT04020510